Mentari Therapeutics, Inc. Common Stock
MTRI
6 hedge funds and large institutions have $515K invested in Mentari Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
263% more capital inflows, than outflows
Capital inflows: $746K | Capital outflows: $205K
4.92% more ownership
Funds ownership: 2.57% → 7.49% (+4.9%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$731K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$11.5K |
| 3 |
Renaissance Technologies
New York
|
+$3.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$80.3K |
| 2 |
Empery Asset Management
New York
|
-$58K |
| 3 |
Two Sigma Investments
New York
|
-$37K |
| 4 |
Two Sigma Securities
New York
|
-$17K |
| 5 |
Millennium Management
New York
|
-$13K |
MTRI Hedge Fund Activity: Q2 2022 in Review
6 of the 5,965 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2022, worth a combined $515K — up 50% from $342K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MTRI and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $731K. The largest seller was Two Sigma Advisers, cutting an estimated $80.3K.
- 6 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2022, down from 8 in Q1 2022.
- Funds reported $515K of Mentari Therapeutics, Inc. Common Stock stock for Q2 2022, up 50% quarter-over-quarter.
- 2 funds opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Mentari Therapeutics, Inc. Common Stock buyer in Q2 2022 was Armistice Capital, an estimated $731K added.
- The largest Mentari Therapeutics, Inc. Common Stock seller in Q2 2022 was Two Sigma Advisers, an estimated $80.3K sold.
Based on aggregated 13F filings for Q2 2022.